Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QTORIN rapamycin in Pachyonychia Congenita
NCT05643872Phase 3Recruiting
- Sponsor
- Palvella Therapeutics
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QTORIN rapamycin in pachyonychia congenita (PC), sponsored by Palvella Therapeutics. Started Nov 2022; status: recruiting.
02
Drugs
QTORIN rapamycin
03
Conditions
pachyonychia congenita (PC)
Beyond the preview
Go deeper on NCT05643872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643872.